Regenxbio Showcases Promising Gene Therapy Data for Hunter Syndrome Treatment
The company reported long-term data demonstrating that its experimental treatment for Hunter syndrome, a rare genetic disorder.
MavriX Bio Receives FDA Fast Track Designation for Angelman Syndrome Treatment
MavriX is a Penn startup company based on technology developed by James Wilson, MD, PhD.
Verismo Therapeutics Announces Clinical Trial Partnership with Miltenyi Biotec
Verismo successfully manufactured its first clinical cell product using viral vector supplied by Miltenyi Bioindustry.
Dispatch Bio Named a 2025 Startup Company to Watch by Endpoints News
The company was recognized for bringing ‘universality’ to cell therapies for solid tumors.
BlueWhale Bio Reaches Major Cell Therapy Clinical Milestone
The company aims to streamline the manufacturing process for huCART19-IL18 cells in the treatment of hematologic cancers.
FDA Approval of New Treatment for Glioma Based on Penn IP
This newly approved therapy is based on technology jointly owned by Penn, Wayne State University and Penn State University.
Smart Dosimetry System (SDS) Accepted into National NSF I-Corps Program
The program awards $50,000 to advance groundbreaking technologies through intensive customer discovery and market validation.
Penn Engineering Researchers Develop Novel Platform to More Efficiently Produce mRNA Delivery Particles
This new method not only allows for rapid production but also enables precise targeting the LNPs to specific organs like the liver, lungs and spleen.
Penn Medicine Researchers Use AI to Uncover Potential Antibiotic Compounds
The researchers used AI to analyze the genomes of tens of thousands of bacteria and other primitive organisms.
Penn Engineers Unlock the Potential for a New Generation of Wireless Communications
Researchers , have developed an adjustable high frequency filter that prevents signal interference in wireless communications and data transfers.